RPRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Repros Therapeutics Inc's cash flow for capital expenditures for the three months ended in Mar. 2016 was $0.00 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Mar. 2016 was $0.00 Mil.
Repros Therapeutics Inc Cash Flow for Capital Expenditures for the trailing twelve months (TTM) ended in Mar. 2016 was 0 (Jun. 2015 ) + 0 (Sep. 2015 ) + 0 (Dec. 2015 ) + 0 (Mar. 2016 ) = $0.00 Mil.
Repros Therapeutics Inc Annual Data
Repros Therapeutics Inc Quarterly Data